Modified Release Gamma-Hydroxybutyrate Formulations
Summary
The European Patent Office published patent application EP3487483A1 for Flamel Ireland Ltd., covering modified release gamma-hydroxybutyrate formulations with improved pharmacokinetics. The patent application designates all EPO member states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR.
What changed
The EPO published international patent application EP3487483A1 for modified release gamma-hydroxybutyrate (GHB) formulations with improved pharmacokinetics. The applicants are Flamel Ireland Ltd. and the inventors include Mégret, Claire, Guillard, Hervé, and Duibuisson, Jean-François. The patent is classified under IPC codes A61K 9/16, A61K 9/50, and A61K 31/19.
This is a standard patent publication providing public notice of the application's existence and claims. No compliance deadlines, regulatory requirements, or enforcement actions are associated with this document. Companies developing competing formulations or generic versions of GHB products should review the claims to assess potential freedom-to-operate considerations.
Archived snapshot
Apr 1, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS
Publication EP3487483A1 Kind: A1 Mar 25, 2026
Applicants
Flamel Ireland Ltd.
Inventors
MÉGRET, Claire, GUILLARD, Hervé, DUIBUISSON, Jean-François
IPC Classifications
A61K 9/16 20060101AFI20180126BHEP A61K 9/50 20060101ALI20180126BHEP A61K 31/19 20060101ALI20180126BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.